{"nctId":"NCT01555957","briefTitle":"Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis","startDateStruct":{"date":"2012-02"},"conditions":["Parenteral Nutrition Associated Cholestasis"],"count":40,"armGroups":[{"label":"low dose intravenous lipids","type":"EXPERIMENTAL","interventionNames":["Drug: intravenous lipid"]},{"label":"high dose of intravenous lipids","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: intravenous lipid"]}],"interventions":[{"name":"intravenous lipid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAll neonates ≥ 34 weeks gestational age with major GI surgical disorders (Gastroschisis, omphalocele, volvulus, trachea-esophageal fistula, duodenal atresia, jejunal atresia, ileal atresia, hirschsprung's disease, anorectal malformation, intestinal obstruction, and GI perforations) requiring surgery admitted to our NICU within first 72 hours will be eligible for this study\n\nExclusion Criteria:\n\n1. If does not need TPN by 72 hours;\n2. Direct hyperbilirubinemia within the first 72 hours after birth;\n3. TORCH infections (Toxoplasmosis, CMV, Herpes, Rubella, HIV, etc);\n4. Biliary tract disorders leading to direct hyperbilirubinemia;\n5. Known metabolic disorders that may be associated with direct hyperbilirubinemia- such as Galactosemia, α-1 antitrypsin deficiency, etc","healthyVolunteers":false,"sex":"ALL","maximumAge":"72 Hours","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Parenteral Nutrition Associated Cholestasis","description":"Defined as direct bilirubin ≥ 2mg/dl developing within one week of the completion of 6 week randomization period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Rate of Change in Direct Bilirubin","description":"Amount of direct (conjugated) bilirubin was measured from sera samples.","paramType":"MEAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":null},{"groupId":"OG001","value":"0.19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Cholestasis"]}}}